Please wait while we prepare everything...
Please wait while we prepare everything...
Please wait while we prepare everything...
Vitreo Retinal Services offer comprehensive medical and surgical management of all Vitreo Retinal diseases with cutting edge technology and at an affordable cost. Common diseases like diabetic retinopathy, vascular blocks, age related macular degeneration and retinal detachment are seen in specialized clinics of retina. Close collaboration with key departments like endocrinology, nephrology, neonatology and intern al medicine helps the patient get appropriate, timely and personalized retinal as well as medical management services, the same day. The right mix of clinical services, clinical research, education and community services are provided by the vitreo retina services. Daily OPD and procedure facilities reduce the waiting time of patients from long distances.
Phone: 0484 – 2851099, 0484 - 6681099
Email: [email protected]
Kerala’s first Anti VEGF monoclonal antibody treatment to the eye.
No injection, sutureless retinal surgery on OPD basis with 25 guage high speed vitrectomy system
Complete Retinal imaging and evaluation facility with FFA, USG, UBM, OCT and electrodiagnosis
Laser therapy for ARMD, diabetic retinopathy, vascular blocks and other diseases Wide angle viewing system for vitreous surgery
The frequently done procedures are OPD procedures and Surgical Retina procedures.
1. What is macular degeneration?
In macular degeneration, the light-sensing cells of the macula malfunction and may over time cease to work. Macular degeneration occurs most often in people over 60 years old, in which case it is called Age Related Macular Degeneration (ARMD). Much less common are several hereditary forms of macular degeneration, which usually affect children or teen-agers. Collectively, they are called Juvenile Macular Degeneration. They include Best’s Disease, Stargardt’s Disease, Sorsby’s Disease and some others.
2. Who gets ARMD?
Macular Degeneration is the leading cause of new blindness in adults over the age of 60 in this country. The disease also causes less severe but significant reductions in the ability to see and perform everyday tasks. A study done by National Eye Institute showed that Macular Degeneration occurs in approximately one out of five people between the ages of 65 to 74. One of three people over age 75 in this country will suffer some visual impairment due to Macular Degeneration.
3. What are the types of ARMD?
The “dry” form of ARMD refers to the atrophic form which is characterized, in its late stages, by the degeneration (i.e. atrophy) of the retina in a region that includes the macula. “Dry” ARMD develops and progresses slowly over a period of 5-10 years or longer. Approximately 85% of the total ARMD patient population has this atrophic form. The less prevalent, “wet” type of ARMD is also referred to as neovascular or exudative ARMD. It is characterized by the ingrowth of new blood vessels from the choroid. “Wet” ARMD progresses much more rapidly, over a period of weeks or months, and usually results in legal blindness in the central portion of the visual field.
4. How do you evaluate ARMD?
Clinical examination, coupled with fluorescein angiography, Optical coherence tomography and in some cases, indocyanine green angiography are the tests useful in finding out the type of ARMD0, its prognosis and outcome.
5. How do you evaluate ARMD? If you have drusen, does that mean you will eventually develop ARMD?
Not necessarily. Many individuals with some drusen do not go on to develop the visual symptoms of ARMD. From a clinical standpoint, drusen must attain a threshold in numbers, size, and shape for them to become a matter of concern to ophthalmologists.
6.What are the risk factors associated with ARMD?
The strongest risk factors are:
Several studies now indicate that diets rich in green leafy vegetables, such as spinach, chard and mustard greens, can reduce the risk of ARMD. These and other vegetables are rich in certain pigments known as carotenoids. Among these, lutein and zeaxanthin are two that are highly concentrated in the macula where they may have effects that protect RPE and/or retinal cells from injury caused by the formation of peroxides and other toxic by-products of the visual cycle . Lutein and zeaxanthin are now widely available as dietary supplements; however, their efficacy when consumed in this form has not been well studied.
There have been at least five published trials that have tried to determine whether dietary supplements, such as vitamins A, C, E or zinc can arrest or prevent the development of ARMD. Thus far, the results from these small scale studies have not been encouraging. However, new data from a much larger study called the Age-Related Eye Disease Study (AREDS) indicates that dietary supplementation with 500 mg of vitamin C, 400 IU of vitamin E, 15 milligrams of beta-carotene and 80 milligrams of zinc (as zinc oxide) can reduce the risk of developing advanced ARMD by approximately 25%.
Earlier, there were no treatments for macular degeneration. About 15 to 20 years back, laser photocoagulation was used for the first time to treat ARMD. For the last 5 years, newer treatments, which are more effective, are coming up. The most commonly applied clinical approach to Age Related Macular Degeneration is one in which in some cases can slow the progression of the disease, but does not restore already lost vision. This is possible with special laser called Photodyanamic therapy. Newer therapeutic approaches include Photodynamic therapy along with intravitreal injections like Lucentis, Macugen or Avastin.
Why see a Retina Specialist ?
Common Retinal Symptoms